Beauty Health CO SKIN
We take great care to ensure that the data presented and summarized in this overview for Beauty Health Co is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SKIN
View all-
Janus Henderson Group PLC London, X010.4MShares$10.3 Million0.01% of portfolio
-
Mirabella Financial Services LLP London, X08.99MShares$8.9 Million1.37% of portfolio
-
Black Rock Inc. New York, NY5.57MShares$5.52 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.4MShares$5.34 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.12MShares$3.09 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ1.89MShares$1.87 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.79MShares$1.77 Million0.0% of portfolio
-
State Street Corp Boston, MA1.68MShares$1.66 Million0.0% of portfolio
-
Silver Point Capital L.P. Greenwich, CT1.59MShares$1.58 Million0.23% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX1.21MShares$1.2 Million0.05% of portfolio
Latest Institutional Activity in SKIN
Top Purchases
Top Sells
About SKIN
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Insider Transactions at SKIN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 09
2025
|
Sheri Lewis CSO and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,296
-3.31%
|
$31,296
$1.08 P/Share
|
|
Apr 09
2025
|
Marla Malcolm Beck President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
92,981
-3.27%
|
$92,981
$1.08 P/Share
|
|
Apr 09
2025
|
Michael P. Monahan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,776
-1.9%
|
$26,776
$1.08 P/Share
|
|
Mar 17
2025
|
Ronald Menezes Chief Revenue Officer |
BUY
Grant, award, or other acquisition
|
Direct |
639,204
+36.31%
|
$639,204
$1.32 P/Share
|
|
Mar 17
2025
|
Sheri Lewis CSO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
639,204
+40.32%
|
$639,204
$1.32 P/Share
|
|
Mar 17
2025
|
Michael P. Monahan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
639,204
+31.2%
|
$639,204
$1.32 P/Share
|
|
Mar 17
2025
|
Marla Malcolm Beck President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,832,386
+39.16%
|
$1,832,386
$1.32 P/Share
|
|
Dec 01
2024
|
Michael P. Monahan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,227
-3.05%
|
$24,227
$1.48 P/Share
|
|
Nov 20
2024
|
Desiree Gruber Director |
SELL
Open market or private sale
|
Direct |
14,663
-10.93%
|
$14,663
$1.5 P/Share
|
|
Aug 12
2024
|
Brent L Saunders Director |
BUY
Open market or private purchase
|
Direct |
40,450
+0.68%
|
$40,450
$1.08 P/Share
|
|
Aug 10
2024
|
Michael P. Monahan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,274
-3.9%
|
$32,274
$1.12 P/Share
|
|
Jul 08
2024
|
Desiree Gruber Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,534
+36.92%
|
-
|
|
Jul 08
2024
|
Brian Christopher Miller Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,534
+31.6%
|
-
|
|
Jul 08
2024
|
Michelle C. Kerrick Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,534
+40.21%
|
-
|
|
Jul 08
2024
|
Doug K. Schillinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,534
+35.45%
|
-
|
|
Jul 08
2024
|
Michael D Capellas Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,534
+22.14%
|
-
|
|
Jul 08
2024
|
Julius Few Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,534
+28.78%
|
-
|
|
Jul 08
2024
|
Brent L Saunders Director |
BUY
Grant, award, or other acquisition
|
Direct |
78,534
+1.32%
|
-
|
|
Apr 09
2024
|
Daniel Copell Watson Chief Revenue Oficer |
BUY
Grant, award, or other acquisition
|
Direct |
243,506
+23.14%
|
-
|
|
Apr 09
2024
|
Marla Malcolm Beck President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
837,662
+43.72%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 4.3M shares |
|---|---|
| Open market or private purchase | 40.5K shares |
| Open market or private sale | 14.7K shares |
|---|---|
| Payment of exercise price or tax liability | 208K shares |